NCT07602166
Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 7 more changesShow less
- Eligibility criteria expanded, about 29 words
- Primary and study completion dates: Jul 2031 to Jul 31, 2031
- Start date changed from estimate of Sep 2026 to Oct 30, 2026
- Secondary endpoints: details revised at 1 of 3 entries
- Study description revised
- Site details revised
- Publications: details revised at 9 of 9 entries
- Notable Start date: Jul 2026 to Sep 2026
- Collaborators expanded, about 5 words
- Minor Study description expanded, about 2 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change in 24-hour ambulatory systolic blood pressure (SBP)
Timeframe: From week 0-4 and week 8-week12
Secondary (3)
FMD
Measurement of oxidative stress and inflammatory cytokines in blood and endothelial cells
Endothelial Cell Harvesting and Analysis
Arms and interventions
Arm 1: Drug-washout-placeboExperimental
Participants with salt sensitivity of blood pressure to receive treatment with 2-HOBA (500mg) three times a day for 4 weeks, followed by a washout period of 4 weeks, and then placebo for 4 weeks
Arm 2: Placebo-washout-DrugExperimental
Participants with salt sensitivity of blood pressure to receive treatment with placebo for 4 weeks followed by a washout period of 4 weeks, and then 2-HOBA (500mg) three times a day for 4 weeks.
Drugs: 2-hydroxybenzylamine, Placebo
Sites
1 site in 1 country
- Vanderbilt University Medical CenterNashville, Tennessee, United States